![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nuo Therapeutics Inc (QB) | USOTC:AURX | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0498 | 14.23% | 0.3998 | 0.271 | 0.3998 | 0.3998 | 0.3998 | 0.3998 | 1,000 | 21:05:50 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 6 , 2017
Nuo Therapeutics, Inc.
(Exact name of Registrant as Specified in Charter)
Delaware |
001-32518 |
23-3011702 |
(State or Other Jurisdiction |
(Commission |
(IRS Employer |
of Incorporation) |
File Number) |
Identification No.) |
207A Perry Parkway, Suite 1, Gaithersburg, MD 20877
(Address of Principal Executive Offices) (Zip Code)
(240) 499-2680
(Registrant ’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02 . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers .
On April 6, 2017, Joseph Del Guercio informed Nuo Therapeutics, Inc. (the “Company”) that he was resigning from the board of directors of the Company (the “Board”), effective upon the appointment of his successor. Effective as of April 7, 2017, the Company’s Board appointed Paul D. Mintz, MD to fill the vacancy created by Mr. Del Guercio’s resignation. The Board also appointed Dr. Mintz to its Compensation Committee and its Nominating and Corporate Governance Committee. Dr. Mintz will be compensated consistent with the compensation program applicable to non-management members of the Board.
On April 10, 2017, the Company issued a press release announcing this change in the membership of the Company’s Board, which is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit Number |
Description |
99.1 |
Press Release of Nuo Therapeutics, Inc., dated April 10, 2017 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Nuo Therapeutics, Inc. |
|
|
|
|
|
|
|
|
|
|
|
By: |
/s/ David E. Jorden |
|
|
|
David E. Jorden |
|
|
|
Chief Executive Officer and Chief Financial Officer |
|
Date: April 10, 2017
1 Year Nuo Therapeutics (QB) Chart |
1 Month Nuo Therapeutics (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions